{"id":5117,"date":"2019-05-23T14:51:32","date_gmt":"2019-05-23T09:21:32","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=5117"},"modified":"2021-07-24T12:57:21","modified_gmt":"2021-07-24T07:27:21","slug":"mercks-keytruda","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/mercks-keytruda","title":{"rendered":"The Business Cocktail"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a002c525d08b\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a002c525d08b\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/mercks-keytruda\/#Merck_decides_to_acquire_Peloton_Therapeutics_fortifying_Oncology_pipeline\" >Merck decides to acquire Peloton Therapeutics, fortifying Oncology pipeline<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/mercks-keytruda\/#Amgen_to_buy_a_drug_discovery_company_Nuevolution\" >Amgen to buy a drug discovery company Nuevolution<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/mercks-keytruda\/#Market_success_of_Keytruda_makes_royalties_an_attractive_asset\" >Market success of Keytruda makes royalties an attractive asset<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/mercks-keytruda\/#K2HV_nets_USD_400_Million_to_support_Healthcare\" >K2HV nets USD 400 Million to support Healthcare<\/a><\/li><\/ul><\/nav><\/div>\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Merck_decides_to_acquire_Peloton_Therapeutics_fortifying_Oncology_pipeline\"><\/span><strong>Merck decides to acquire Peloton Therapeutics, fortifying Oncology pipeline <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>Merck <\/strong>is ready to buy <strong>Peloton Therapeutics<\/strong> for <strong>USD 1.1 million<\/strong>. The companies have entered into a definitive agreement which will give Merck rights over an oral HIF-2\u03b1 inhibitor- <strong>PT2977<\/strong>, which is Peloton\u2019s lead candidate for the treatment of renal cancer. The collaboration will help Merck achieve its goal to develop novel therapies through innovative research for the treatment of cancer. PT2977 here is underway for multiple clinical studies specifically for von Hippel-Lindau (VHL) disease-associated <a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-renal-cell-carcinoma-mrcc-pipeline-insight\">renal cell carcinoma<\/a> (RCC).<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Amgen_to_buy_a_drug_discovery_company_Nuevolution\"><\/span><strong>Amgen to buy a drug discovery company Nuevolution<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p> <strong>Amgen\u00a0<\/strong>has announced to buy\u00a0<strong>Nuevolution<\/strong>&#8211; a Scandinavian dug maker biopharmaceutical company. The whole deal had cost Amgen a sum of\u00a0<strong>USD 167 million<\/strong>. The acquisition will let Amgen have control over Nuevolution\u2019s excessive\u00a0<a href=\"https:\/\/www.delveinsight.com\/report-store\/cervical-cancer-market\">cancer\u00a0<\/a>pipeline. In the past decade, Nuevolution has made its name by signing deals with various major Pharma and Biotech companies like GlaxoSmithKline, Johnson &amp; Johnson, Merck and Novartis. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Market_success_of_Keytruda_makes_royalties_an_attractive_asset\"><\/span><strong>Market success of Keytruda makes royalties an attractive asset<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>Merck\u2019s <\/strong>blockbuster <a href=\"https:\/\/www.delveinsight.com\/report-store\/medullary-thyroid-cancer-market\">cancer <\/a>immunotherapy <strong>Keytruda <\/strong>has been adding to the revenue of Merck so far. The rising sales of the drug have resulted in a Canadian government pension plan shelling out USD 1.3 billion in buying partial shares to Keytruda from <strong>Lifearc<\/strong>. Lifearc is a charity responsible for handling intellectual property rights on discoveries made under the United Kingdom&#8217;s Medical Research Council.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"K2HV_nets_USD_400_Million_to_support_Healthcare\"><\/span><strong>K2HV nets USD 400 Million to support Healthcare<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>K2 HealthVentures<\/strong> has raised <strong>USD 400 Million<\/strong> to support healthcare and life sciences companies. The company has decided to provide debt financing to enable companies to achieve research milestones. Financing and support worth USD 10 million to USD 50 million to help pharma companies grow over the long term. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck decides to acquire Peloton Therapeutics, fortifying Oncology pipeline Merck is ready to buy Peloton Therapeutics for USD 1.1 million. The companies have entered into a definitive agreement which will give Merck rights over an oral HIF-2\u03b1 inhibitor- PT2977, which is Peloton\u2019s lead candidate for the treatment of renal cancer. The collaboration will help Merck [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5118,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[831,4205,4202,345,395],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-5117","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-amgen","tag-k2-health-ventures","tag-k2hv","tag-keytruda","tag-merck","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>The Business Cocktail 23\/05\/2019 - DelveInsight Business Research<\/title>\n<meta name=\"description\" content=\"Merck\u2019s blockbuster cancer immunotherapy Keytruda...rising sales of the drug have resulted in a Canadian government pension plan shelling out USD 1.3 bn...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/mercks-keytruda\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Business Cocktail 23\/05\/2019 - DelveInsight Business Research\" \/>\n<meta property=\"og:description\" content=\"Merck\u2019s blockbuster cancer immunotherapy Keytruda...rising sales of the drug have resulted in a Canadian government pension plan shelling out USD 1.3 bn...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/mercks-keytruda\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-05-23T09:21:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09021239\/Business-23-may.png\" \/>\n\t<meta property=\"og:image:width\" content=\"647\" \/>\n\t<meta property=\"og:image:height\" content=\"345\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"The Business Cocktail 23\/05\/2019 - DelveInsight Business Research","description":"Merck\u2019s blockbuster cancer immunotherapy Keytruda...rising sales of the drug have resulted in a Canadian government pension plan shelling out USD 1.3 bn...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/mercks-keytruda","og_locale":"en_US","og_type":"article","og_title":"The Business Cocktail 23\/05\/2019 - DelveInsight Business Research","og_description":"Merck\u2019s blockbuster cancer immunotherapy Keytruda...rising sales of the drug have resulted in a Canadian government pension plan shelling out USD 1.3 bn...","og_url":"https:\/\/www.delveinsight.com\/blog\/mercks-keytruda","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-05-23T09:21:32+00:00","article_modified_time":"2021-07-24T07:27:21+00:00","og_image":[{"width":647,"height":345,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09021239\/Business-23-may.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/mercks-keytruda","url":"https:\/\/www.delveinsight.com\/blog\/mercks-keytruda","name":"The Business Cocktail 23\/05\/2019 - DelveInsight Business Research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/mercks-keytruda#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/mercks-keytruda#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09021239\/Business-23-may.png","datePublished":"2019-05-23T09:21:32+00:00","dateModified":"2021-07-24T07:27:21+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Merck\u2019s blockbuster cancer immunotherapy Keytruda...rising sales of the drug have resulted in a Canadian government pension plan shelling out USD 1.3 bn...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/mercks-keytruda"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/mercks-keytruda#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09021239\/Business-23-may.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09021239\/Business-23-may.png","width":647,"height":345,"caption":"Business cocktail"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09021239\/Business-23-may-300x160.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Amgen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">K2 Health Ventures<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">K2HV<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Keytruda<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Merck<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Amgen<\/span>","<span class=\"advgb-post-tax-term\">K2 Health Ventures<\/span>","<span class=\"advgb-post-tax-term\">K2HV<\/span>","<span class=\"advgb-post-tax-term\">Keytruda<\/span>","<span class=\"advgb-post-tax-term\">Merck<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on May 23, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on May 23, 2019 2:51 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"Business cocktail","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5117","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=5117"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5117\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/5118"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=5117"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=5117"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=5117"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=5117"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=5117"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}